Canadian guidelines on sexually transmitted infections : treatment of N. gonorrhoeae in response to the discontinuation of spectinomycin : alternative treatment guidance statement.: HP40-1/2017-3-1E-PDF
"The Public Health Agency of Canada (PHAC) has been informed that manufacturing of spectinomycin has been discontinued. Spectinomycin is recommended in the Canadian Guidelines on Sexually Transmitted Infections (CGSTI) as part of an alternate combination therapy for anogenital Neisseria gonorrhoeae infection, in individuals with contraindications to first-line treatment (i.e., cephalosporins given in combination with azithromycin or doxycycline). This guidance statement for alternative treatments for gonococcal infections was developed in consultation with the CGSTI Expert Working Group based on Canadian epidemiology and a rapid evidence review”--Issue, p. 1.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.840166&sl=0
| Department/Agency |
|
|---|---|
| Title | Canadian guidelines on sexually transmitted infections : treatment of N. gonorrhoeae in response to the discontinuation of spectinomycin : alternative treatment guidance statement. |
| Variant title |
|
| Publication type | Monograph |
| Language | [English] |
| Other language editions | [French] |
| Earlier edition | Canadian guidelines on sexually transmitted infections |
| Format | Digital text |
| Electronic document | |
| Note(s) |
|
| Publishing information |
|
| Description | 4 p. |
| ISBN | 978-0-660-09142-6 |
| Catalogue number |
|
| Departmental catalogue number | 170170 |
| Edition |
|
| Subject terms |
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.Page details
- Date modified: